NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 6.53 against a street estimate of 6.10 — a beat of 7.0%.
with an average price target of ₹863.33.
| Document | Date |
|---|---|
| Q1 FY27 earnings call AKUMS DRUGS & PHARMACEUTICALS LIMITED Q1 FY27 EARNINGS SUMMARY --- HEADLINE NUMBERS • Operating Revenue: INR1,167 crores, up 13.9% YoY (Q1 FY26: IN | 2026-08-13 |
| Investor presentation · Q1 FY27 AKUMS DRUGS AND PHARMACEUTICALS LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue: Rs 1,167 Cr – growth of 13.9% year-on-year (YoY), up | 2026-08-08 |
| Quarterly results · Q1 FY27 AKUMS DRUGS AND PHARMACEUTICALS LIMITED – SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q1 FY2026-27 (Quarter ended 30 June 2026) – Standalone bas | 2026-08-08 |
| Annual report FY2026 AKUMS DRUGS AND PHARMACEUTICALS LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Total Income: ₹44,877 Million (7.6% growth year-on-year) • Consolida | 2026-06-18 |
| Q4 FY26 earnings call AKUMS DRUGS & PHARMACEUTICALS LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue FY26: INR 4,359 crores (+5.8% YoY from INR 4,170 crores | 2026-05-21 |
| Investor presentation · Q4 FY26 AKUMS DRUGS AND PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Total Revenue: ₹4,359 crore (+5.8% YoY); Q4 FY26 Revenue: ₹1,158 | 2026-05-14 |
| Quarterly results · Q4 FY26 AKUMS DRUGS AND PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from operations (FY 2025-26): ₹13,117.84 million (vs. ₹13,487 | 2026-05-14 |
| Q3 FY26 earnings call AKUMS DRUGS & PHARMACEUTICALS LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Operating Revenue: INR 1,160 crores (Q3 FY26) – up 14.8% YoY from INR 1,0 | 2026-02-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹1 / share ex-date Jul 3, 2026 | 2026-07-03 |
| Announcement | Date |
|---|---|
| Acquisition of Oriflame India's manufacturing business ITC Limited has announced the acquisition of Oriflame India's manufacturing business. Under SEBI regulations, the company must disclose material events that could affect shareholders. Key D | 2026-07-23 |
| Incorporation of joint venture company announced Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Incorporation of Joint Venture Company'. | 2025-10-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Akums Drugs and Pharmaceutical — free to start.
Google PlayApp StoreData updated 2026-09-18.